Development of a UPLC-MS/MS method for the quantification of sildenafil by DBS, and its use on pediatric pulmonary hypertension

Bioanalysis

Volumn 6, Issue 21, 2014, Pages 2815-2824

  Zavala, Leticia Contreras ^a   Espinosa, Liliana Rivera ^b   Moreno, Alionka P Ángeles ^c   San Juan, Eduardo Ramírez ^a   Hernández, Sergio Zamudio ^a   González, Alberto García ^d   Jiménez, Gabriel Marcelín ^d  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b SECRETARÍA DE SALUD   (Mexico)

^c Molecular Biology Laboratory   (Mexico)

^d Global Bioanalytical Consulting   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

N DESMETHYL SILDENAFIL; SILDENAFIL; UNCLASSIFIED DRUG; VARDENAFIL; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONAMIDE; VASODILATOR AGENT;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CALIBRATION; CONTROLLED STUDY; DRIED BLOOD SPOT TESTING; DRUG DETERMINATION; DRUG HALF LIFE; DRUG METABOLISM; ERYTHROCYTE MEMBRANE; HEMATOCRIT; HEMOLYSIS; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MEXICO; PH; PULMONARY HYPERTENSION; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDITY; VISCOSITY; BLOOD; CHILD; DRUG MONITORING; FEMALE; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTENSION, PULMONARY; MALE; PRESCHOOL CHILD; TANDEM MASS SPECTROMETRY;

CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRIED BLOOD SPOT TESTING; DRUG MONITORING; FEMALE; HALF-LIFE; HUMANS; HYPERTENSION, PULMONARY; MALE; PIPERAZINES; PURINES; SULFONAMIDES; TANDEM MASS SPECTROMETRY; VASODILATOR AGENTS;

EID: 84918495986     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.14.126     Document Type: Article

References (14)

1. Oishi P, Datar SA, and Fineman JR. Advances in the management of pediatric pulmonary hypertension. Respir. Care 56(9), 1314-1339 (2011).
2. Simonneau G, Robbins IM, Beghetti M et al. Updated clinical classifcation for pulmonary hypertension. J. Am. Coll. Cardiol.54(Suppl. 1), S43-S54 (2009).
3. Blumenthal DK, Garrison JC. Pharmacodynamics: molecular mechanisms of drug action. In: The pharmalogical basis of Therapuetics (12th Edition). Brunton LL, Chabner BA, Knollman BC (Eds). Goodman & Gilman's, New York, NY, USA, 41-72 (2011).
4. Barst RJ, Ivy DD, Gaitán G et al. A randomized double-blind, placebo controlled dose-ranging study of oral sildenafl citrate in treatment-naïve children with pulmonary arterial hypertension. Circulation 125, 324-334 (2012).
5. Yassen H, Darwich M, and Hamdy H. Is sildenafl an effective therapy in the management of persistent pulmonary hypertension? J. Clin. Neonatol. 1(4), 171-175 (2012).
6. Li W, and Tse F. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed. Chromatogr.24, 49-65 (2010).
7. Edelbroek PM, Van der Heijden J, and Stolck LM. Dried blood spot methods in therapeutic drug monitoring: methods, assays and pitfalls. Ther. Drug. Monit.31(3), 327-336 (2009).
8. Guidance for Industry. Bioanalytical Method Validation-Draft Guidance-. U.S. Department of Health & Human Services. Food & Drug Administration. (CDER) (September 2013). www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf
9. Timmerman P, White S, Globig S et al. EBF recommendation on the validation of bioanalytical methods for dried blood spots. Bioanalysis 3 (14), 1567-1575 (2011).
10. Timmerman P, White S, Cobb Z et al. Update of the EBF recommendation for the use of DBS in the regulated bioanalysis integrating the conclusions from the EBF DBS-Microsampling Consortium. Bioanalysis 5(17), 2129-2136 (2013).
11. Marcelín-Jiménez G, Ángeles-Moreno A, Contreras-Zavala L et al. Comparison of fasting bioavailability among 100-mg commercial, 100-mg generic, and 50-mg chewable generic sildenafl tablets in healthy male Mexican volunteers. J. Clin. Pharmacol. Therap.34(3), 689-698 (2012).
12. Chaumais M, Perrin S, Sitbon O et al. Pharmacokinetic evaluation of sildenafl as a pulmonary hypertension treatment. Expert Opin. Drug Metab. Toxicol.9(9), 1193-1205 (2013).
13. Roldan T, Deiros L, Romero JA et al. Safety and tolerability of targeted therapies for pulmonary hypertension in children. Pediatr. Cardiol. 35(3), 490-498 (2014).
14. Maxey DM, Ivy DD, Ogawa MT et al. Food and Drug Administration (FDA) postmarket reported side effects and adverse events associated with pulmonary hypertension therapy in pediatric patients. Pediatr. Cardiol. 34(7), 1628-1636 (2013).